CD44 and ovarian carcinoma: In addition, previous studies have shown that in ovarian cancer cells, paclitaxel-HA conjugate interacted with CD44, entered the cells through a receptor-mediated mechanism, and exerted a concentration-dependent inhibitory effect on tumor cell growth48.